BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 18.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 198,695 shares of the medical equipment provider's stock after purchasing an additional 31,167 shares during the quarter. Envestnet Asset Management Inc. owned about 0.43% of BioLife Solutions worth $5,158,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC purchased a new position in BioLife Solutions during the 4th quarter valued at $26,000. 1620 Investment Advisors Inc. boosted its holdings in BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after acquiring an additional 675 shares during the period. Smartleaf Asset Management LLC boosted its holdings in BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock valued at $117,000 after acquiring an additional 950 shares during the period. KLP Kapitalforvaltning AS purchased a new position in BioLife Solutions during the 4th quarter valued at $171,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in BioLife Solutions during the 4th quarter valued at $201,000. Hedge funds and other institutional investors own 93.24% of the company's stock.

Insider Transactions at BioLife Solutions

In other news, CMO Todd Berard sold 1,577 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the transaction, the chief marketing officer now directly owns 104,961 shares of the company's stock, valued at approximately $2,624,025. The trade was a 1.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sarah Aebersold sold 5,771 shares of the company's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $130,770.86. Following the transaction, the insider now directly owns 80,094 shares in the company, valued at $1,814,930.04. This represents a 6.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 72,127 shares of company stock valued at $1,676,533. Corporate insiders own 2.20% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BLFS. HC Wainwright boosted their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, March 6th. StockNews.com cut BioLife Solutions from a "hold" rating to a "sell" rating in a report on Thursday. Finally, Northland Securities upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat, BioLife Solutions currently has a consensus rating of "Moderate Buy" and an average target price of $31.17.

BioLife Solutions Stock Down 1.9 %

Shares of BLFS stock traded down $0.48 during mid-day trading on Monday, hitting $24.47. The stock had a trading volume of 415,547 shares, compared to its average volume of 377,379. BioLife Solutions, Inc. has a 12-month low of $17.15 and a 12-month high of $29.55. The firm has a market capitalization of $1.16 billion, a P/E ratio of -23.08 and a beta of 1.93. The firm's 50-day moving average is $24.14 and its two-hundred day moving average is $25.28. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the previous year, the company posted ($0.21) EPS. On average, analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.